Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ecopipam - Teva Pharmaceutical Industries

Next Previous
Drug Profile

Ecopipam - Teva Pharmaceutical Industries

Alternative Names: EBS-101; Ecopipam HCl; Ecopipam Hydrochloride; PSYRX 101; SCH-39166

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Emalex Biosciences; Psyadon Pharmaceuticals; Schering-Plough; Teva Pharmaceutical Industries
  • Class Alcohols; Antipsychotics; Behavioural disorder therapies; Benzazepines; Cardiovascular therapies; Chlorinated hydrocarbons; Drug withdrawal therapies; Heterocyclic compounds with 4 or more rings; Naphthalenes; Obesity therapies; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lesch-Nyhan syndrome; Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Gilles de la Tourette's syndrome
  • Phase III Lesch-Nyhan syndrome
  • Phase II Speech disorders
  • Phase I/II Restless legs syndrome
  • No development reported Cardiovascular disorders; Gambling
  • Discontinued Cocaine-related disorders; Obesity; Schizophrenia

Most Recent Events

  • 19 Aug 2026 FDA assigns PDUFA action date of 30/09/2026 for (drug) for Gilles de la Tourette's syndrome
  • 19 Aug 2026 The US FDA accepts NDA for Ecopipam for Gilles de la Tourette's syndrome for review
  • 19 Aug 2026 The US FDA grants Priority Review for ecopipam for Gilles de la Tourette's syndrome

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top